Aldeyra Therapeutics

Aldeyra Therapeutics

Aldeyra Therapeutics started in 2004, founded by Todd C. Brady to address elevated reactive aldehyde species (RASP) as drivers of inflammatory pathology. Based in Lexington, Massachusetts, the company has focused its entire operational history on discovering and developing novel small-molecule therapeutics that trap these toxic aldehydes, a mechanism distinct from standard anti-inflammatory or immunosuppressive approaches. Its asset base is a concentrated pipeline of wholly owned candidates built around the RASP platform. The lead program, reproxalap, targets dry eye disease and allergic conjunctivitis. In pivotal trials, reproxalap met its primary endpoints in allergic conjunctivitis, but the FDA issued a Complete Response Letter in November 2023 for the dry eye disease indication, citing insufficient data to support efficacy. A second candidate, ADX-2191, designed for vitreoretinal lymphoma and retinitis pigmentosa, received FDA Orphan Drug designation but faced its own regulatory reset when Aldeyra paused development after a Phase 2 analysis. The firm's geographic footprint is US-centric, though its clinical sites span global ophthalmology centers in North America and Europe. Aldeyra has funded its development through equity offerings and at-the-market programs rather than conventional venture fund structures, with no disclosed co-investment vehicles or philanthropic arms. Total deployment to date is not reported as AUM but as cumulative R&D spend; the firm does not manage external capital. In 2024, Aldeyra regrouped around its pipeline and began preparing a resubmission path for reproxalap, citing additional analyses from its trials and ongoing discussions with the FDA. Structurally, Aldeyra's differentiator is its singular focus on the aldehyde-trapping mechanism — a biochemical niche few other public biotechs occupy — combined with a CEO-founder who has maintained the same scientific thesis for two decades. That longevity of scientific commitment, paired with no external capital management mandate, makes the firm's strategic decisions purely pipeline-driven.